479 Fc-competent fully human anti-TIGIT blocking monoclonal antibodies demonstrated potent anti-tumor efficacy in preclinical models

479 Fc-competent fully human anti-TIGIT blocking monoclonal antibodies demonstrated potent anti-tumor efficacy in preclinical models

Bibliographic Details
Main Authors:	Xin Zhang, Jing Zhang, Yang Chen, Yi Yang, Weiqiu Lan, Baihong Liu, W Frank An, Chaoshe Guo
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models
by: Xin Chen, et al.
Published: (2022-02-01)

1175 YH006, a fully human Treg-depleting CTLA-4×OX40 bispecific antibody, demonstrates superior preclinical efficacy and favorable developability
by: Xiang Guo, et al.
Published: (2023-11-01)

Generating Anti-TIGIT and CD155 Monoclonal Antibodies for Tumor Immunotherapy
by: Yu-Hang Duan, et al.
Published: (2022-09-01)

587 Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models
by: John Williams, et al.
Published: (2020-11-01)

475 Fc-silent anti-TIGIT antibodies potentiate anti-tumor immunity without depleting regulatory T cells
by: Paul Foster, et al.
Published: (2023-11-01)

1383 Preclinical characterization of D3L-002, a novel cancer immunotherapy bispecific antibody that elicits potent anti-tumor efficacy via co-blocking TIGIT and PVRIG
by: Jia Wang, et al.
Published: (2023-11-01)

Pharmacokinetic‐pharmacodynamic modelling of the anti‐FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic
by: Rocio Lledo‐Garcia, et al.
Published: (2022-01-01)

Fc-competent multispecific PDL-1/TIGIT/LAG-3 antibodies potentiate superior anti-tumor T cell response
by: Riyao Yang, et al.
Published: (2023-06-01)

Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation
by: Jin-Hwan Han, et al.
Published: (2020-10-01)

253 Anti-TIGIT antibodies require enhanced FcγR co-engagement for optimal T and NK cell-dependent anti-tumor immunity
by: Rebecca Ward, et al.
Published: (2020-11-01)

Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer
by: Beilei Lou, et al.
Published: (2021-09-01)

Nonfucosylation of an anti-TIGIT antibody enhances FcγR engagement, driving innate immune activation and antitumor activity
by: Alyson J. Smith, et al.
Published: (2023-11-01)

Corrigendum: Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation
by: Jin-Hwan Han, et al.
Published: (2020-11-01)

TIGIT-Fc as a Potential Therapeutic Agent for Fetomaternal Tolerance
by: Wenyan Fu, et al.
Published: (2021-03-01)

Production and characterization of monoclonal antibodies anti fragment Fc of bovine IgG
by: Tânia Regina Penha, et al.
Published: (2010-02-01)

479 AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results
by: Andrea Bullock, et al.
Published: (2021-11-01)

Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro
by: Omar S. Qureshi, et al.
Published: (2024-12-01)

277 SynNotch-CAR T cells demonstrate potent anti-tumor efficacy in a preclinical immunocompetent mouse model for glioblastoma
by: Yuan Wang, et al.
Published: (2023-11-01)

Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT)
by: Shuguang Zuo, et al.
Published: (2021-02-01)

Unravelling the potent anti-oxidant and anti-inflammatory actions of plumbagin: A review of preclinical discoveries
by: Aanchal Verma, et al.
Published: (2024-03-01)

TIGIT/CD226 Axis Regulates Anti-Tumor Immunity
by: Jinah Yeo, et al.
Published: (2021-02-01)

Fully human monoclonal antibody inhibitors of the neonatal Fc receptor (FcRn) reduce circulating IgG in nonhuman primates
by: Andrew E Nixon, et al.
Published: (2015-04-01)

1165 Preclinical evaluation of fully human bispecific antibody-drug candidates targeting HER3 and the juxtamembrane region of MUC1
by: Yi Yang, et al.
Published: (2023-11-01)

Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity
by: Chris Liang, et al.
Published: (2022-03-01)

Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells
by: Kate J. Dixon, et al.
Published: (2021-01-01)

Anti-FcαRI Monoclonal Antibodies Resolve IgA Autoantibody-Mediated Disease
by: Amelie Bos, et al.
Published: (2022-03-01)

Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies
by: Dean A Lee, et al.
Published: (2023-12-01)

Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies
by: Martin J. Scott, et al.
Published: (2020-01-01)

Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
by: Brazel D, et al.
Published: (2023-01-01)

HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models
by: Hang Ke, et al.
Published: (2023-04-01)

485 TIGIT/PVRIG humanized mice-an idea model for studying anti-PVRIG antibodies
by: Xiang Gao, et al.
Published: (2023-11-01)

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
by: Mathieu Grapin, et al.
Published: (2019-06-01)

Novel application of anti‐human Fc nanobody for screening high‐producing CHO cells for monoclonal antibody
by: Di Zhu, et al.
Published: (2022-10-01)

Preclinical Evaluation of Liposomal C8 Ceramide as a Potent anti-Hepatocellular Carcinoma Agent.
by: Huiqing Lv, et al.
Published: (2016-01-01)

XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer
by: Zhen Liu, et al.
Published: (2023-12-01)

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
by: Yiwen Li, et al.
Published: (2018-04-01)

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer
by: Marina Martinez, et al.
Published: (2021-01-01)

AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
by: Wei Tan, et al.
Published: (2023-10-01)

Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function
by: Jennifer L. Schwedler, et al.
Published: (2024-12-01)

1152 DM001: A novel bispecific ADC targeting TROP2 and EGFR with potent anti-tumor efficacy in PDX models
by: Yi Yang, et al.
Published: (2023-11-01)